Overview
PEPS ranks this pair inside the Top 300 market-cap universe. That means Injective and PC0000031 are liquid enough for an indexable comparison, with metrics refreshed on the hourly coin pipeline.
Quick winners
Full comparison
| Metric | INJ | PC0000031 |
|---|---|---|
| Price | $5.15 | $1,880.52 |
| Market Cap | $490.41M | $202.50M |
| FDV | — | — |
| Volume 24h | $2.50M | $0.000000 |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 98.00 | 159.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | PC0000031 |
|---|---|---|
| 1H | — | — |
| 24H | +5.19% | +0.00% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | PC0000031 |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.47 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 63.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Use the indicator table as a checklist: if momentum and trend align on one asset while the other diverges, relative-value setups become more interesting — still without certainty.
Fundamentals
| Metric | INJ | PC0000031 |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
PC0000031
Pros and cons
Pros of Injective
- Market-cap scale on Injective may dampen some idiosyncratic shocks versus smaller peers.
- INJ often anchors narratives that attract sustained media and analyst coverage.
- Composite PEPS readings for Injective can surface clearer module agreement during trend phases.
- Injective typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
Cons of Injective
- Indicator stacks on Injective may stay stretched longer than expected in strong trends.
- Crowded positioning around INJ sometimes amplifies squeeze or flush risk.
- Large-cap status for Injective can mean slower percentage upside versus high-beta alternatives.
Pros of PC0000031
- PC0000031 can offer higher relative beta when market attention rotates toward its niche.
- Narrative optionality around PC0000031 can reprice quickly when catalysts appear.
- If technical momentum aligns, PC0000031 may outperform on medium-term windows.
Cons of PC0000031
- Higher volatility on PC0000031 cuts both ways and demands stricter risk limits.
- Weaker market-cap standing may leave PC0000031 more exposed to liquidity droughts.
Which looks stronger right now?
Statistically, higher market cap (Injective) often correlates with deeper books, while hotter 24h prints (Injective) can fade. Position sizing should reflect that uncertainty.
AI summary
This AI-assisted summary starts from live PEPS fields. Injective holds market-cap $490.41M and rank #98; PC0000031 shows $202.50M and #159. Where liquidity and flow matter, watch Injective. Where durability matters, watch Injective. AI composite scores (48.70/58.40) compress those tensions into a single lens. In probabilistic terms, the side winning more columns may have a nearer-term edge, but tails remain fat. Revisit after the next hourly refresh.
FAQ
Which is better, Injective or PC0000031?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or PC0000031?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and PC0000031.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.